RARE Daily

Gingko Bioworks Acquires Three Companies, Launches Technology Network

February 28, 2024

Rare Daily Staff

Gingko Bioworks, a systems integrator building a leading platform for cell programming and biosecurity, has acquired three tools companies and launched the Ginkgo Technology Network, an ecosystem of 25 technology partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing that are committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.

Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets and help eliminate the siloing and switching costs limiting R&D progress.

“It’s time to eliminate the difficult – and importantly, false – choices our customers face when they are deciding how to grow new products with biology,” said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. “With the Ginkgo Technology Network, our customers don’t have to wrestle on their own with the integration of different vendors or, worse, prematurely choose an approach for biological designs or analysis.”

The company also added three companies’ technology to its growing portfolio of genetic medicines services. Ginko acquired Proof Diagnostics, founded by gene pioneer Feng Zhang of the Broad Institute of MIT and Harvard, Drs. Omar Abudayyeh and Jonathan Gootenberg of the McGovern Institute for Brain Research at MIT, and Sid Shenai to develop a low cost, rapid, easy-to-use, and sensitive diagnostic system – for SARS-CoV-2, Flu A/B, RSV and other diseases, including oncology – using CRISPR-based and other technologies. Proof’s libraries of OMEGA (Obligate Mobile Element Guided Activity) RNA programmable, non-Cas enzymes and associated intellectual property are the key focus of Ginkgo’s acquisition.

Ginko acquired key assets of Reverie Labs to accelerate drug discovery, including Reverie’s infrastructure and software for training large-scale AI foundation models and four of Reverie’s key AI team members who will join Ginkgo. The acquisition is intended to strengthen Ginkgo’s AI/ML-driven discovery services offering and to accelerate Ginkgo’s work to build next-generation biological foundation models.

Finally, Gingko acquired Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines. The acquisition is intended to strengthen Ginkgo’s gene therapy, cell therapy, and RNA therapeutics services offerings. Ginkgo will incorporate Patch’s machine learning models and downstream assays into its existing platform, making new capabilities in synthetic promoter and untranslated region (UTR) engineering available to partners. Additionally, Patch’s validated muscle promoters and robust RNA UTRs complement Ginkgo’s circular RNA and promoter screening platform technology, which is already accelerating customer program progress.

Photo: Jason Kelly, CEO and co-founder of Ginkgo Bioworks

Stay Connected

Sign up for updates straight to your inbox.